Biotech firms Genmab and Incyte are joining forces to test a new combination therapy targeting KRAS G12D-mutated colorectal cancer, a common and difficult-to-treat malignancy.
Genmab is expanding the clinical utility of its bispecific antibody, petosemtamab, by entering a collaboration with Incyte to test it in combination with INCB161734 and standard-of-care chemotherapy. This move targets the high unmet medical need in first-line KRAS G12D-mutated metastatic colorectal cancer, diversifying the asset's development beyond its existing HNSCC and wild-type CRC programs.
To evaluate the combination of petosemtamab, INCB161734, and standard-of-care chemotherapy as a first-line treatment for patients with KRAS G12D-mutated metastatic colorectal cancer.
Genmab will conduct the Phase 1/2 study, while Incyte will co-fund the research and provide the clinical supply of INCB161734.
Incyte is leveraging its KRAS G12D inhibitor, INCB161734, in a new strategic partnership with Genmab to address metastatic colorectal cancer. By co-funding this trial, Incyte aims to validate the efficacy of its inhibitor in a novel combination therapy, further strengthening its oncology pipeline and expanding the potential indications for its KRAS-targeted asset.
It is an investigational, selective, and orally bioavailable small molecule KRAS G12D inhibitor being developed for solid tumors.
It allows Incyte to explore the potential of combining KRAS G12D inhibition with LGR5-targeted EGFR inhibition and chemotherapy, aiming to advance a new first-line treatment approach.
Genmab and Incyte have launched a clinical trial collaboration to evaluate a novel combination therapy for KRAS G12D-mutated metastatic colorectal cancer. The Phase 1/2 study will pair Genmab’s petosemtamab with Incyte’s INCB161734 and standard chemotherapy, aiming to address a significant unmet need in first-line treatment for patients with this aggressive mutation.
The companies aim to evaluate the safety and efficacy of combining petosemtamab and INCB161734 with chemotherapy as a first-line treatment for patients with KRAS G12D-mutated metastatic colorectal cancer.